{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:20:17Z","timestamp":1784557217487,"version":"3.55.0"},"reference-count":0,"publisher":"Bioscientifica","issue":"1","content-domain":{"domain":["erc.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:p>Renal hyperparathyroidism (rHPT) is a complex and challenging disorder. It develops early in the course of renal failure and is associated with increased risks of fractures, cardiovascular disease and death. It is treated medically, but when medical therapy cannot control the hyperparathyroidism, surgical parathyroidectomy is an option. In this review, we summarize the pathophysiology, diagnosis, and medical treatment; we describe the effects of renal transplantation; and discuss the indications and strategies in parathyroidectomy for rHPT. Renal hyperparathyroidism develops early in renal failure, mainly as a consequence of lower levels of vitamin D, hypocalcemia, diminished excretion of phosphate and inability to activate vitamin D. Treatment consists of supplying vitamin D and reducing phosphate intake. In later stages calcimimetics might be added. RHPT refractory to medical treatment can be managed surgically with parathyroidectomy. Risks of surgery are small but not negligible. Parathyroidectomy should likely not be too radical, especially if the patient is a candidate for future renal transplantation. Subtotal or total parathyroidectomy with autotransplantation are recognized surgical options. Renal transplantation improves rHPT but does not cure it.<\/jats:p>","DOI":"10.1530\/erc-19-0284","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T09:31:21Z","timestamp":1573032681000},"page":"R21-R34","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":20,"title":["The treatment of renal hyperparathyroidism"],"prefix":"10.1530","volume":"27","author":[{"given":"Martin","family":"Almquist","sequence":"first","affiliation":[{"name":"1Department of Clinical Sciences Lund, Department of Surgery Section of Endocrine and Sarcoma Lund, Sk\u00e5ne University Hospital, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin","family":"Isaksson","sequence":"additional","affiliation":[{"name":"2Department of Clinical Sciences Malm\u00f6, Urology Malm\u00f6, Faculty of Medicine, Sk\u00e5ne University Hospital, Lund University, Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Clyne","sequence":"additional","affiliation":[{"name":"3Department of Clinical Sciences Lund, Nephrology Lund, Faculty of Medicine, Sk\u00e5ne University Hospital, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","container-title":["Endocrine-Related Cancer"],"original-title":[],"link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/27\/1\/ERC-19-0284.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/27\/1\/ERC-19-0284.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:55:24Z","timestamp":1784555724000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/erc\/article\/27\/1\/R21-R34\/25328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":0,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1530\/erc-19-0284","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}